Atara Biotherapeutics Inc (ATRA NASDAQ) stock market data APIs
$4.4592
0(0%)
as of February 13, 2026
Try our APIs with
free plan!
Atara Biotherapeutics Inc Financial Data Overview
Price chart is built with
Anychart
Atara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with cancer and autoimmune disease in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) with post-transplant lymphoproliferative disease, as well as other EBV-driven diseases. The company has research collaboration agreements with Memorial Sloan Kettering Cancer Center, and Council of the Queensland Institute of Medical Research. Atara Biotherapeutics, Inc. was incorporated in 2012 and is headquartered in Thousand Oaks, California.
Prev. Close
4.4592
Open
4.4753
High
4.645
Low
4.454
52 wk Range
4.2-19.145
Market Cap
32 086 K
P/E Ratio
1.5669
Shares Outstanding
7 210 K
Revenue
152 M
EPS
-0.32
Beta
-0.417
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Atara Biotherapeutics Inc (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Atara Biotherapeutics Inc data using free add-ons & libraries
Get Atara Biotherapeutics Inc Fundamental Data
Atara Biotherapeutics Inc Fundamental data includes:
- Net Revenue: 152 M
- EBITDA: 44 852 K
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-11-12
- EPS/Forecast: -0.26
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Atara Biotherapeutics Inc News
New
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Atara Biotherapeutics, Inc. - ATRA
NEW YORK, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Atara Biotherapeutics, Inc. (“Atara” or the “Company”) (NASDAQ: ATRA). Such inve...
Top Midday Decliners
Travere Therapeutics (TVTX) said the US Food and Drug Administration extended the review timeline of PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscri...
Atara Biotherapeutics Stock Falls After FDA CRL On EBVALLO BLA
(RTTNews) - Atara Biotherapeutics Inc. (ATRA) announced that the U.S. Food and Drug Administration issued a Complete Response Letter (CRL) for the Biologics License Application (BLA) of EBVALLO (tabel...
Top Midday Decliners
Atara Biotherapeutics (ATRA) said Monday the US Food and Drug Administration is "unable" to approve PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscrip...
Get Atara Biotherapeutics Inc fresh news feed via Financial News API
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
